Once a rising star in the biotech industry, Bluebird Bio (NASDAQ: BLUE) has had a difficult past few years. The company's shares are down by 94% since late 2018, a horrible performance by any metric. However, this biotech specialist has some redeeming qualities. Unlike most of its peers in the gene-editing niche, Bluebird has earned approval for several of its products, a testament to the company's innovative abilities.
Furthermore, Bluebird's market capitalization is just $314 million as of this writing, lower than many of its clinical-stage competitors. Is Bluebird Bio stock a buy at current levels?
Source Fool.com